Loading…

Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer

Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healt...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-10, Vol.24 (20), p.15232
Main Authors: Biniari, Georgia, Markatos, Christos, Nteli, Agathi, Tzoupis, Haralambos, Simal, Carmen, Vlamis-Gardikas, Alexios, Karageorgos, Vlasios, Pirmettis, Ioannis, Petrou, Panagiota, Venihaki, Maria, Liapakis, George, Tselios, Theodore
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53
container_end_page
container_issue 20
container_start_page 15232
container_title International journal of molecular sciences
container_volume 24
creator Biniari, Georgia
Markatos, Christos
Nteli, Agathi
Tzoupis, Haralambos
Simal, Carmen
Vlamis-Gardikas, Alexios
Karageorgos, Vlasios
Pirmettis, Ioannis
Petrou, Panagiota
Venihaki, Maria
Liapakis, George
Tselios, Theodore
description Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.
doi_str_mv 10.3390/ijms242015232
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771910558</galeid><doaj_id>oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4</doaj_id><sourcerecordid>A771910558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</originalsourceid><addsrcrecordid>eNptkl1v0zAUhiMEYmNwyb0lboZEhh3ny1eo66CtNAmphWvrxB-Zq8Tu7KSof5NfhLNWQBHKRY7s532SY58keUvwDaUMfzTbPmR5hkmR0exZcknyLEsxLqvnf9UXyasQthhHpGAvkwta1SxnJLtMfq5hMM5Ch-5UMK39gDYHOzzEOiCwEt0aK41t0UxrY81wQJthlEYF5DSaRdDD42issyrmvdlH2T5uzp3dji0MSqLBoUX0Szd4tzM2XatOQZiUS-f7KXi9sOvl-2iDzrVjTA_uB3gZ0CaiYhKiVd-P1oVxt_MqhPi_0-dP-fRO7ZSVyg5oDlYo_zp5oaEL6s3pfZV8__L523yZ3n9drOaz-1TkdTakDZZaMwKl1KTJoGCyYlUsS12UWdnopiigoZTkAkBKWueVUjIvRVWCFFgX9CpZHb3SwZbvvOnBH7gDw58WnG85-MGITnFSUq0lKVXGSK5KaEADY5hRVVFBdB5dn46u3dj0SorYjYfuTHq-Y80Db92eE1ziipQ4Gq5PBu8e4ykOvDdBqK4Dq9wYeFbXtKjznLGIvvsH3brRx-N_ouKEFKSq_1AtxA6M1fEGQUxSPqsqwgguiom6-Q8VH6l6I-L1aBPXzwLpMSC8C8Er_btJgvk00fxsoukv1UjtKQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882595178</pqid></control><display><type>article</type><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</creator><creatorcontrib>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</creatorcontrib><description>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms242015232</identifier><identifier>PMID: 37894912</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Cancer ; Cancer therapies ; Chemical bonds ; Cytotoxicity ; Drug delivery systems ; Drugs ; Gonadotropin ; gonadotropin-releasing hormone (GnRH) ; hormone-dependent cancer ; Human reproduction ; Hypothalamus ; Immunotherapy ; Medical research ; Medicine, Experimental ; mitoxantrone ; Ovaries ; Peptides ; Pituitary hormones ; Prostate ; targeted cancer therapy ; Thioredoxin ; thioredoxin system ; Toxicity ; Vehicles</subject><ispartof>International journal of molecular sciences, 2023-10, Vol.24 (20), p.15232</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</cites><orcidid>0000-0003-4933-7723 ; 0000-0002-3789-8032 ; 0009-0000-5789-8884 ; 0000-0002-1534-2762 ; 0000-0001-5068-6459 ; 0009-0001-9386-7169 ; 0000-0003-0022-3725 ; 0000-0002-7096-4281 ; 0000-0002-1310-0591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2882595178/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2882595178?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Biniari, Georgia</creatorcontrib><creatorcontrib>Markatos, Christos</creatorcontrib><creatorcontrib>Nteli, Agathi</creatorcontrib><creatorcontrib>Tzoupis, Haralambos</creatorcontrib><creatorcontrib>Simal, Carmen</creatorcontrib><creatorcontrib>Vlamis-Gardikas, Alexios</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Pirmettis, Ioannis</creatorcontrib><creatorcontrib>Petrou, Panagiota</creatorcontrib><creatorcontrib>Venihaki, Maria</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><creatorcontrib>Tselios, Theodore</creatorcontrib><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><title>International journal of molecular sciences</title><description>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemical bonds</subject><subject>Cytotoxicity</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Gonadotropin</subject><subject>gonadotropin-releasing hormone (GnRH)</subject><subject>hormone-dependent cancer</subject><subject>Human reproduction</subject><subject>Hypothalamus</subject><subject>Immunotherapy</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>mitoxantrone</subject><subject>Ovaries</subject><subject>Peptides</subject><subject>Pituitary hormones</subject><subject>Prostate</subject><subject>targeted cancer therapy</subject><subject>Thioredoxin</subject><subject>thioredoxin system</subject><subject>Toxicity</subject><subject>Vehicles</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1v0zAUhiMEYmNwyb0lboZEhh3ny1eo66CtNAmphWvrxB-Zq8Tu7KSof5NfhLNWQBHKRY7s532SY58keUvwDaUMfzTbPmR5hkmR0exZcknyLEsxLqvnf9UXyasQthhHpGAvkwta1SxnJLtMfq5hMM5Ch-5UMK39gDYHOzzEOiCwEt0aK41t0UxrY81wQJthlEYF5DSaRdDD42issyrmvdlH2T5uzp3dji0MSqLBoUX0Szd4tzM2XatOQZiUS-f7KXi9sOvl-2iDzrVjTA_uB3gZ0CaiYhKiVd-P1oVxt_MqhPi_0-dP-fRO7ZSVyg5oDlYo_zp5oaEL6s3pfZV8__L523yZ3n9drOaz-1TkdTakDZZaMwKl1KTJoGCyYlUsS12UWdnopiigoZTkAkBKWueVUjIvRVWCFFgX9CpZHb3SwZbvvOnBH7gDw58WnG85-MGITnFSUq0lKVXGSK5KaEADY5hRVVFBdB5dn46u3dj0SorYjYfuTHq-Y80Db92eE1ziipQ4Gq5PBu8e4ykOvDdBqK4Dq9wYeFbXtKjznLGIvvsH3brRx-N_ouKEFKSq_1AtxA6M1fEGQUxSPqsqwgguiom6-Q8VH6l6I-L1aBPXzwLpMSC8C8Er_btJgvk00fxsoukv1UjtKQ</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Biniari, Georgia</creator><creator>Markatos, Christos</creator><creator>Nteli, Agathi</creator><creator>Tzoupis, Haralambos</creator><creator>Simal, Carmen</creator><creator>Vlamis-Gardikas, Alexios</creator><creator>Karageorgos, Vlasios</creator><creator>Pirmettis, Ioannis</creator><creator>Petrou, Panagiota</creator><creator>Venihaki, Maria</creator><creator>Liapakis, George</creator><creator>Tselios, Theodore</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4933-7723</orcidid><orcidid>https://orcid.org/0000-0002-3789-8032</orcidid><orcidid>https://orcid.org/0009-0000-5789-8884</orcidid><orcidid>https://orcid.org/0000-0002-1534-2762</orcidid><orcidid>https://orcid.org/0000-0001-5068-6459</orcidid><orcidid>https://orcid.org/0009-0001-9386-7169</orcidid><orcidid>https://orcid.org/0000-0003-0022-3725</orcidid><orcidid>https://orcid.org/0000-0002-7096-4281</orcidid><orcidid>https://orcid.org/0000-0002-1310-0591</orcidid></search><sort><creationdate>20231001</creationdate><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><author>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemical bonds</topic><topic>Cytotoxicity</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Gonadotropin</topic><topic>gonadotropin-releasing hormone (GnRH)</topic><topic>hormone-dependent cancer</topic><topic>Human reproduction</topic><topic>Hypothalamus</topic><topic>Immunotherapy</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>mitoxantrone</topic><topic>Ovaries</topic><topic>Peptides</topic><topic>Pituitary hormones</topic><topic>Prostate</topic><topic>targeted cancer therapy</topic><topic>Thioredoxin</topic><topic>thioredoxin system</topic><topic>Toxicity</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biniari, Georgia</creatorcontrib><creatorcontrib>Markatos, Christos</creatorcontrib><creatorcontrib>Nteli, Agathi</creatorcontrib><creatorcontrib>Tzoupis, Haralambos</creatorcontrib><creatorcontrib>Simal, Carmen</creatorcontrib><creatorcontrib>Vlamis-Gardikas, Alexios</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Pirmettis, Ioannis</creatorcontrib><creatorcontrib>Petrou, Panagiota</creatorcontrib><creatorcontrib>Venihaki, Maria</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><creatorcontrib>Tselios, Theodore</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Health and Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biniari, Georgia</au><au>Markatos, Christos</au><au>Nteli, Agathi</au><au>Tzoupis, Haralambos</au><au>Simal, Carmen</au><au>Vlamis-Gardikas, Alexios</au><au>Karageorgos, Vlasios</au><au>Pirmettis, Ioannis</au><au>Petrou, Panagiota</au><au>Venihaki, Maria</au><au>Liapakis, George</au><au>Tselios, Theodore</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>24</volume><issue>20</issue><spage>15232</spage><pages>15232-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37894912</pmid><doi>10.3390/ijms242015232</doi><orcidid>https://orcid.org/0000-0003-4933-7723</orcidid><orcidid>https://orcid.org/0000-0002-3789-8032</orcidid><orcidid>https://orcid.org/0009-0000-5789-8884</orcidid><orcidid>https://orcid.org/0000-0002-1534-2762</orcidid><orcidid>https://orcid.org/0000-0001-5068-6459</orcidid><orcidid>https://orcid.org/0009-0001-9386-7169</orcidid><orcidid>https://orcid.org/0000-0003-0022-3725</orcidid><orcidid>https://orcid.org/0000-0002-7096-4281</orcidid><orcidid>https://orcid.org/0000-0002-1310-0591</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2023-10, Vol.24 (20), p.15232
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4
source Publicly Available Content (ProQuest); PubMed Central
subjects Cancer
Cancer therapies
Chemical bonds
Cytotoxicity
Drug delivery systems
Drugs
Gonadotropin
gonadotropin-releasing hormone (GnRH)
hormone-dependent cancer
Human reproduction
Hypothalamus
Immunotherapy
Medical research
Medicine, Experimental
mitoxantrone
Ovaries
Peptides
Pituitary hormones
Prostate
targeted cancer therapy
Thioredoxin
thioredoxin system
Toxicity
Vehicles
title Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A34%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rational%20Design,%20Synthesis%20and%20Binding%20Affinity%20Studies%20of%20Anthraquinone%20Derivatives%20Conjugated%20to%20Gonadotropin-Releasing%20Hormone%20(GnRH)%20Analogues%20towards%20Selective%20Immunosuppression%20of%20Hormone-Dependent%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Biniari,%20Georgia&rft.date=2023-10-01&rft.volume=24&rft.issue=20&rft.spage=15232&rft.pages=15232-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms242015232&rft_dat=%3Cgale_doaj_%3EA771910558%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2882595178&rft_id=info:pmid/37894912&rft_galeid=A771910558&rfr_iscdi=true